Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Comprehensive clinical nephrology,
[2.]
F.P. Schena.
Epidemiology of end-stage renal disease: International comparisons of renal replacement therapy.
Kidney Int, 57 (2000), pp. S39-S45
[3.]
Comité de Registro de la SEN.
Registro Nacional de Diálisis y Trasplante de la Sociedad Española de Nefrología correspondiente al año 1998.
Nefrología, 20 (2000), pp. 34-42
[4.]
E. Burgess.
Conservative treatment to slow deterioration of renal function: evidence-based recommendations.
Kidney Int, 70 (1999), pp. S17-S25
[5.]
M.J. Klag, P.K. Whelton, B.L. Randall, J.D. Neaton, F.L. Brancati, C.E. Foud.
Blood pressure and end-stage renal disease in men.
N Eng J Med, 334 (1996), pp. 13-18
[6.]
J.T. McCarthy.
A practical approach to the management of patients with chronic renal failure.
Mayo Clin Proc, 74 (1999), pp. 269-273
[8.]
J.A. Delmez, E. Slatopolsky.
Hyperphosphatemia: its consequences and treatment in chronic renal failure.
Am J Kidney Dis, 19 (1992), pp. 303-317
[9.]
K.A. Hruska, S.L. Teitelbaum.
Mechanisms of disease: Renal osteodystrophy.
N Eng J Med, 333 (1995), pp. 166-174
[10.]
E.A. Slatopolsky, S.K. Burke, M.A. Dillon.
and the RenaGel study group. RenaGel, a nonabosrbed calcium –and aluminum–free phosphate binder, lowers serum phosphorus and parathyroid hormone.
Kidney Int, 55 (1999), pp. 299-307
[11.]
L.R. Baker, L. Abrams, C.J. Roe, M.C. Faugese, P. Fanti, Y. Subayti, et al.
1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial.
Kidney Int, 36 (1989), pp. 661
[12.]
N.A. Hamdy, J.A. Kanis, M.N. Beneton, C.B. Brown, J.R. Juttarann, J.G. Jordans, et al.
Effect of alfacalcidol on natural course of renal bone disease in jild to moderate renal failure.
BMJK, 310 (1995), pp. 358
[13.]
J.W. Eschbach.
Erythropoietin: the promise and the facts.
Kidney Int, 45 (1994), pp. S70-S76
[14.]
M. Martínez-Maldonado, J.L. Rodicio, J. Herrera-Acosta.
Tratado de nefrología (2.a ed.).
[15.]
A.M. Davison, J.S. Cameron, J.P. Grünfeld, D.N.S. Kerr, E. Ritz, Gh.G. Winearls.
Oxford textbook of clinical nephrology (2.a ed.).
[16.]
R. Jofre, J.M. López-Gomez, F. Valderrábano.
Quality of life form patient groups.
Kidney Int, 57 (2000), pp. S121-S130
[17.]
F. Moreno, J.M. López-Gomez, D. Sanz Guajardo, R. Jofre, F. Valderrábano.
The Spanish Cooperative Renal Patients Quality of Life Study Group: quality of life in dialysis patients. A Spanish multicentre study.
Nephrol Dial Transplant, 11 (1996), pp. 125-129
[18.]
N. Mazzuchi, J.M. Fernández-Cean, E. Carbonell.
Criteria for selection of ESRD treatment modalities.
Kidney Int, 57 (2000), pp. S136-S143
[19.]
R. Martín-Hernández.
Análisis de los costes en nefrología: situación actual y perspectivas de futuro.
Nefrología, 17 (1998), pp. 40-51
[20.]
P. Lázaro.
Evaluación de las tecnologías alternativas para la insuficiencia renal crónica: eficacia, equidad.
Nefrología, 17 (1994), pp. 49-60
Copyright © 2001. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
